Chapter 28 Psychiatry Flashcards
5-HT
Seratonin
Seratonin acronym
5-HT
dopamine acronym
DA
MAOI acronym
monoamine oxidase inhibitor
monoamine oxidase inhibitor acronym
MAOI
MDD vs MDE
major depressive disorder vs episode
SGA
SGA second generation antipsychotics
SNRI
SNRI serotonin and norepinephrine reuptake inhibitors
TCA
TCA tricyclic antidepressant
Screening Questions for Major
-pearl from t notes 16
• Have you been feeling down, depressed or hopeless?
• Do you feel anxious or worry about things?
• Has there been a time in your life where you have felt euphoric, extremely talkative, had a lot of energy,
and a decreased need for sleep?
• Do you see or hear things that you think other people cannot?
• Have you ever thought of harming yourself or committing suicide?
Mental state Exam
Appearance Behavior Conversation (thought form and content ex:delusions) Affect, mood Perception (hallucination) Cognition Judgement Insight Rapport
Multiaxial Assessment
Axis I: differential diagnosis of DSM-5 clinical disorders
• Axis II: personality disorders, developmental disability
• Axis III: general medical conditions potentially relevant to understanding/management of the
mental disorder
• Axis IV: psychosocial and environmental issues
• Axis V: Global Assessment of Functioning (GAF, 0 to 100) incorporating effects of axes I to IV
Axis I:
Axis I: differential diagnosis of DSM-5 clinical disorders
• Axis II
• Axis II: personality disorders, developmental disability
Axis III
• Axis III: general medical conditions potentially relevant to understanding/management of the
mental disorder
• Axis IV:
• Axis IV: psychosocial and environmental issues
• Axis V:
• Axis V: Global Assessment of Functioning (GAF, 0 to 100) incorporating effects of axes I to IV
General management in psychiatry, 3 things
biological (e.g. pharmacotherapy),
psychological (e.g. CBT), and social (e.g. support group)
What is a delusion?
fixed, false beliefs
Hallucinations:
Hallucinations: perceptual experiences
without an external stimulus
Psychotic disorder definition
- characterized by a significant impairment in reality testing
- delusions or hallucinations
3 psychotic disorders based on time
brief psychotic disorder >one day to <1 month
schizophreniform disorder 1-6 months
schizophrenia >6months
Schizophrenia
1epidemiology, Etiology, Pathophysiology, Comorbidity, Management, Course and Prognosis
- prevalence: 0.3-0.7%, M:F = 1:1
- mean age of onset: females late-20s; males early- to mid-20s
- suicide risk: 10% die by suicide, 30% attempt suicide
Schizophrenia
epidemiology, 1Etiology, Pathophysiology, Comorbidity, Management, Course and Prognosis
multifactorial: disorder is a result of interaction between both biological and environmental factors
Schizophrenia
epidemiology, Etiology, 1Pathophysiology, Comorbidity, Management, Course and Prognosis
- neurodegenerative theory
* neurodevelopmental theory
Schizophrenia
epidemiology, Etiology, Pathophysiology, 1Comorbidity, Management, Course and Prognosis
• substance-related disorders
• anxiety disorders
• decreased life expectancy because of associated medical conditions (e.g. weight gain, diabetes,
metabolic syndrome, CV/pulmonary disease)
Schizophrenia
epidemiology, Etiology, Pathophysiology, Comorbidity, 1Management, Course and Prognosis
1 biological / somatic (acute treatment and maintenance: antipsychotics (haloperidol, risperidone, olanzipine,
paliperidone; clozapine if refractory);
adjunctive: ± mood stabilizers (for aggression/impulsiveness - lithium, valproate,
carbamazepine) ± anxiolytics ± ECT
treat for at least 1-2 years after the first episode, at least 5 years after multiple episodes
(relapse causes severe deterioration)
2 psychosocial
3 psychotherapy:
Schizophrenia
epidemiology, Etiology, Pathophysiology, Comorbidity, Management, 1Course and Prognosis
• majority of individuals display some type of prodromal phase
• course is variable: some individuals have exacerbations and remissions and others remain
chronically ill; accurate prediction of the long-term outcome is not possible
• negative symptoms may be prominent early in the illness and may become more prominent and
more disabling later on; positive symptoms appear and typically diminish with treatment
• over time: 1/3 improve, 1/3 remain the same, 1/3 worsen
neurodegenerative theory
neurodegenerative theory
• natural history may be a rapid or gradual decline in function and ability to communicate
• glutamate system may mediate progressive degeneration by excitotoxic mechanism which leads to
production of free radicals
neurodevelopmental theory
• neurodevelopmental theory: abnormal development of the brain from prenatal life
• neurons fail to migrate correctly, make inappropriate connections, and break down in later life
• inappropriate apoptosis during neurodevelopment resulting in faulty connections between
neurons
schitzophrenia good prognostic indicators
• Acute onset • Shorter duration of prodrome • Female gender • Good cognitive functioning • Good premorbid functioning • No family history • Presence of affective symptoms • Absence of structural brain abnormalities • Good response to drugs • Good support system
Schizoaffective DSM criteria A
A. concurrent psychosis (criterion A of schizophrenia) and major mood episode - uninterrupted
period of illness
Schizoaffective DSM criteria B
B. delusions or hallucinations for 2 or more wk in the absence of a major mood episode during the
lifetime duration of the illness
Schizoaffective DSM criteria C
C. major mood episode symptoms are present for the majority of the total duration of the active
and residual periods of the illness
Delusional disorder criteria A
A. the presence of one (or more) delusions with a duration of 1 mo or longer
Delusional disorder criteria B
B. criterion A for schizophrenia has never been met
Note: hallucinations, if present, are not prominent and are related to the delusional theme
Delusional disorder Treatment
• psychotherapy, antipsychotics, antidepressants
mood disorders defintion
mood disorders are characterized by the presence of diagnosable mood episodes
mood episodes definition
mood episodes represent a combination of symptoms comprising a predominant mood state that
is abnormal in quality or duration (e.g. major depressive, manic, mixed, hypomanic). DSM-5
Criteria for mood episodes are listed below.
Medical Workup for a Mood Disorder
• routine screening: physical exam, CBC, thyroid function test, extended electrolytes, urinalysis,
drug screen, medications list
• additional screening: neurological consultation, chest X-ray, ECG, CT head
Major Depressive Episode criteria A
≥5 of the following symptoms have been present during the same 2 wk period and represent a
change from previous functioning; at least one of the symptoms is either 1) depressed mood or
2) loss of interest or pleasure (anhedonia)
MSIGECAPS Mood: depressed Sleep: increased/decreased Interest: decreased Guilt Energy: decreased Concentration: decreased Appetite: increased/decreased Psychomotor: agitation/retardation Suicidal ideation
Major Depressive Episode criteria B
the symptoms cause clinically significant distress or impairment in social, occupational, or other
important areas of functioning
Major Depressive Episode criteria C
the episode is not attributable to the direct physiological effects of a substance or a GMC
Manic Episode Criteria A
a distinct period of abnormally and persistently elevated, expansive, or irritable mood and
abnormally and persistently increased goal-directed activity or energy, lasting ≥1 wk and present
most of the day, nearly every day (or any duration if hospitalization is necessary)
Manic Episode Criteria B
during the period of mood disturbance and increased energy or activity, ≥3
Criteria for Mania (≥3) GST PAID Grandiosity Sleep (decreased need) Talkative Pleasurable activities, Painful consequences Activity Ideas (flight of) Distractible
Manic Episode criteria C
the mood disturbance is sufficiently severe to cause marked impairment in social or occupational
functioning or to necessitate hospitalization to prevent harm to self or others, or there are
psychotic features
HypoManic Episode
• criterion A and B of a manic episode is met, but duration is ≥4 d
• episode associated with an uncharacteristic change in functioning that is observable by others
but not severe enough to cause marked impairment in social or occupational functioning or to
necessitate hospitalization
• absence of psychotic features. (If these are present the episode is, by definition, manic)
Major Depressive Disorder criteria A
presence of a MDE
Major Depressive Disorder criteria B
the MDE is not better accounted for by schizoaffective disorder and is not superimposed on
schizophrenia, schizophreniform disorder, delusional disorder, or psychotic disorder NOS
Major Depressive Disorder criteria C
there has never been a manic episode or a hypomanic episode
MDD single vs recurrent
single vs. recurrent is an episode descriptor that carries prognostic significance. Recurrent is
classified as the patient having two or more distinct MDE episodes; to be considered separate the
patient must have gone 2 consecutive months without meeting criteria
MDD
1epidemiology, etiology, risk factors, treatment, prognosis
- lifetime prevalence: 12%
* peak prevalence age 15-25 yr (M:F = 1:2)
MDD
epidemiology, 1etiology, risk factors, treatment, prognosis
- biological
2. psychosocial
MDD
epidemiology, etiology, 1risk factors, treatment, prognosis
- sex: F>M, 2:1
- family history: depression, alcohol abuse, suicide attempt or completion
- childhood experiences: loss of parent before age 11, negative home environment (abuse, neglect)
- personality: neuroticism, insecure, dependent, obsessional
- recent stressors: illness, financial, legal, relational, academic
- lack of intimate, confiding relationships or social isolation
- low socioeconomic status
MDD
epidemiology, etiology, risk factors, 1treatment, prognosis
Treatment
• lifestyle: increased aerobic exercise, mindfulness-based stress reduction, zinc supplementation
• biological: SSRIs, SNRIs, other antidepressants, somatic therapies (see Pharmacotherapy, PS44, and
Somatic Therapies, PS52)
1st line pharmacotherapy: sertraline, escitalopram, venlafaxine, mirtazapine
more options, read toronto notes
• psychological
individual therapy (psychodynamic, interpersonal, CBT), family therapy, group therapy
• social: vocational rehabilitation, social skills training
• experimental: magnetic seizure therapy, deep brain stimulation, vagal nerve stimulation, ketamine
MDD
epidemiology, etiology, risk factors, treatment, 1prognosis
one year after diagnosis of MDD without treatment: 40% of individuals still have symptoms that
are sufficiently severe to meet criteria for MDD, 20% continue to have some symptoms that no
longer meet criteria for MDD, 40% have no mood disorder
MDD biological Treatment options
1st line pharmacotherapy: sertraline, escitalopram, venlafaxine, mirtazapine
for partial or non-response can change class or add augmenting agent: buproprion,
quetiapine-XR, aripiprazole, lithium
typical response to antidepressant treatment: physical symptoms improve at 2 wk, mood/
cognition by 4 wk, if no improvement after 4 wk at a therapeutic dosage alter regimen
ECT: currently fastest and most effective treatment for MDD. Consider in severe, psychotic
or treatment-resistant cases
rTMS: early data support efficacy equivalent to ECT with good safety and tolerability
phototherapy: especially if seasonal component, shift work, sleep dysregulation